Crescent Biopharma vs Immunome
CBIO and IMNM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBIO and IMNM compare
Immunome is the larger company, worth 4.1 times as much as Crescent Biopharma ($2.1B against $526M).
Crescent Biopharma keeps more of each dollar of sales as profit, with a net margin of −728% compared with −5594% at Immunome.
Crescent Biopharma scores higher on the StockData Score (10 against 6 for Immunome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBIO | IMNM |
|---|---|---|
| Size and price | ||
| Market cap | $526M | $2.1B |
| Share price | $14.15 | $18.77 |
| Change, 1 year | 8.4% | 7.7% |
| Change, 5 years | −92.5% | 9.1% |
| Beta (5Y) | 1.63 | 1.74 |
| Employees | 44 | 177 |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 35.0× (better) | 531× |
| P/B | 1.9× (better) | 4.7× |
| FCF yield | −15.7% | −9.6% (better) |
| Growth | ||
| Revenue growth (TTM) | – | −63.3% |
| Revenue growth, 5Y average | 1.3% | – |
| Profitability | ||
| Operating margin | −1217% (better) | −5948% |
| Net margin | −728% (better) | −5594% |
| FCF margin | −550% (better) | −5119% |
| Return on equity | −55.8% (better) | −62.5% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 12.57 (better) | 11.66 |
| Altman Z-score | 10.43 | 21.85 (better) |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 79.7% | 104% |
| Held by insiders | 38.6% | 6.4% |
| Insider net buying, 12 months | $29.1M (better) | −$25.2M |
| Short interest, % of float | 18.3% | 15.2% |
Go deeper
- CBIO stock overview
- CBIO income statement
- CBIO valuation and score
- IMNM stock overview
- IMNM income statement
- IMNM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.